New Delhi-based startup HempStreet has raised $1 million in Pre-Series A round. The round was led by their existing investor Carl Waahlin, a serial entrepreneur and investor, with an investment portfolio of over $200 million ( via Waahlin Holdings) across various verticals including CBD based products in North America. Other investors in this round include existing investor Andre Rodrigues and a clutch of HNIs from South East Asia, along with Abhishek Mohan, Founder and CEO of HempStreet who also participated. 

The company will use the funds to expand its activities around clinical trials for proprietary formulations, solidify itself as a leader in the menstrual cramps and pain treatment segment and facilitate R&D to further develop ayurveda-inspired products that will be put through the clinical validation process.

To expand its global footprint, HempStreet has partnered with MGC Pharma (UK), Gynica (Israel), Amrita School of Ayurveda (India), UIDI (Brazil) and Cannabis 360 (Brazil). In 2024, the company aims to enter Latam and North America to launch a line of clinically backed products starting with their proprietary formulation to tackle  primary and secondary Dysmenorrhea.

Recently, HempStreet partnered with myUpchar.com to introduce 'Manmath Ras' - a product specifically designed to address common sexual health issues in men. HempStreet has received a total funding amount of $3 million till date and works with 20,000 doctors across India.